STOCK TITAN

Fractyl Health (NASDAQ: GUTS) 2026 meeting backs board and auditor

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Fractyl Health, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected three Class II directors and ratified the company’s independent auditor. Ian Sheffield, Marc Elia, and Clive Meanwell were elected to three-year terms ending at the 2029 annual meeting.

Of 158,648,963 common shares outstanding as of April 17, 2026, 112,236,206 were represented at the meeting, reflecting approximately 70.7% of the voting power. Shareholders also approved the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares outstanding 158,648,963 shares Common stock outstanding as of April 17, 2026
Shares represented 112,236,206 shares Represented at 2026 Annual Meeting
Voting power represented 70.7% Percentage of common stock entitled to vote at meeting
Votes for auditor 107,931,959 votes For ratification of Ernst & Young LLP
Votes for Ian Sheffield 73,761,318 for; 464,966 withheld Election as Class II director
Votes for Marc Elia 65,196,683 for; 9,029,601 withheld Election as Class II director
Votes for Clive Meanwell 63,701,054 for; 10,525,230 withheld Election as Class II director
Annual Meeting of Stockholders financial
"On June 10, 2026, Fractyl Health, Inc. held its 2026 Annual Meeting of Stockholders."
broker non-vote financial
"Director Nominee | For | Withheld | Broker Non-Vote Marc Elia | 65,196,683 | 9,029,601 | 38,009,922"
independent registered public accounting firm financial
"The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"Emerging growth company Item 5.07 Submission of Matters to a Vote of Security Holders."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
proxy statement regulatory
"each of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2026"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
0001572616false00015726162026-06-102026-06-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2026

 

 

Fractyl Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41942

27-3553477

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3 Van de Graaff Drive

Suite 200

 

Burlington, Massachusetts

 

01803

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 902-8800

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.00001 par value per share

 

GUTS

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 10, 2026, Fractyl Health, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 158,648,963 shares of the Company’s common stock outstanding as of the record date of April 17, 2026, 112,236,206 shares were represented at the Annual Meeting, either by proxy or by attending the meeting, representing approximately 70.7% in voting power of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The matters voted on at the Annual Meeting, each of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2026, and the votes cast with respect to each such matter are set forth below:

1. Election of Class II Directors

The election of the following individuals as Class II directors, each for a three-year term ending at the 2029 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal:

Director Nominee

For

Withheld

Broker Non-Vote

Marc Elia

65,196,683

9,029,601

38,009,922

Clive Meanwell, M.B., Ch.B., M.D.

63,701,054

10,525,230

38,009,922

Ian Sheffield

73,761,318

464,966

38,009,922

 

2. Ratification of Independent Auditors

The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:

For

Against

Abstain

107,931,959

189,715

4,114,532

 

Based on the foregoing votes, each of Marc Elia, Clive Meanwell, M.B., Ch.B., M.D., and Ian Sheffield were elected as directors and Item 2 was approved.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Fractyl Health, Inc.

 

 

 

 

Date:

June 11, 2026

By:

/s/ Harith Rajagopalan

 

 

 

Harith Rajagopalan, M.D., Ph.D.
Co-Founder, Chief Executive Officer and Director
(Principal Executive Officer)

 

 


FAQ

What did Fractyl Health (GUTS) shareholders vote on at the 2026 Annual Meeting?

Shareholders voted on electing three Class II directors and ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. All proposals described in the proxy statement were approved at the meeting.

Who was elected to Fractyl Health (GUTS) Class II board seats in 2026?

Marc Elia, Clive Meanwell, M.B., Ch.B., M.D., and Ian Sheffield were elected as Class II directors for three-year terms ending at the 2029 annual meeting. Each will serve until a successor is elected and qualified or earlier departure.

What was shareholder turnout at Fractyl Health’s 2026 Annual Meeting?

Out of 158,648,963 common shares outstanding on April 17, 2026, 112,236,206 shares were represented in person or by proxy. This represented approximately 70.7% of the company’s voting power entitled to vote at the meeting.

Did Fractyl Health (GUTS) shareholders ratify Ernst & Young as auditor for 2026?

Yes. Shareholders ratified the appointment of Ernst & Young LLP as Fractyl Health’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification proposal received substantially more votes for than against.

How did Fractyl Health shareholders vote on the director nominees in 2026?

For Marc Elia, 65,196,683 votes were for and 9,029,601 withheld. For Clive Meanwell, 63,701,054 were for and 10,525,230 withheld. For Ian Sheffield, 73,761,318 were for and 464,966 withheld, with 38,009,922 broker non-votes for each.

What were the vote totals on Fractyl Health’s 2026 auditor ratification proposal?

The proposal to ratify Ernst & Young LLP as independent registered public accounting firm received 107,931,959 votes for, 189,715 against, and 4,114,532 abstentions. Based on these votes, the auditor ratification proposal was approved by shareholders.

Filing Exhibits & Attachments

1 document